Pharmaceuticals India

India Neuropathic Pain Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Neuropathic Pain Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $173.6 Mn Placeholder estimate
Estimate 2025 $187.8 Mn 2% of the global market
Projected 2034 $381.7 Mn 103.3% Adds $193.9 Mn over 9 forecast years
CAGR 2025–2034 8.2% Faster than 17% of 180 Pharmaceuticals markets here
Key players 5
  • India is 2% of the global market.
  • In APAC, the largest is China at $858.3 Mn.
  • Fastest growing: India (this report) at 8.2% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$193.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuropathic Pain Treatment Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $173.6 Mn — —
2025 (base) $187.8 Mn +$14.2 Mn —
2026 (forecast) $203.2 Mn +$15.4 Mn +8.2%
2027 (forecast) $219.8 Mn +$16.7 Mn +17.1%
2028 (forecast) $237.9 Mn +$18.0 Mn +26.7%
2029 (forecast) $257.4 Mn +$19.5 Mn +37.1%
2030 (forecast) $278.5 Mn +$21.1 Mn +48.3%
2031 (forecast) $301.3 Mn +$22.8 Mn +60.5%
2032 (forecast) $326.0 Mn +$24.7 Mn +73.6%
2033 (forecast) $352.8 Mn +$26.7 Mn +87.9%
2034 (forecast) $381.7 Mn +$28.9 Mn +103.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Neuropathic Pain Treatment Market Analysis at a glance
Market size, 2025$187.8 Mn placeholder estimate
Forecast, 2034$381.7 Mn placeholder estimate
Growth (CAGR), 2025–20348.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersPfizer Inc., Eli Lilly and Company, Vertex Pharmaceuticals, Grunenthal, Daiichi Sankyo Company (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Neuropathic Pain Treatment Market Analysis Executive Summary

Neuropathic pain treatments ease pain from damaged nerves, such as in diabetes, shingles and spinal injury.

Key segments of the neuropathic Pain Treatment market include drug class (Anticonvulsants, Antidepressants and Topical Agents) and indication (Diabetic Neuropathy, Postherpetic Neuralgia and Spinal Cord Injury).

Bar chart: India Neuropathic Pain Treatment market size, 2024–2034, placeholder estimates. $173.6 Mn in 2024, $187.8 Mn in 2025 and $381.7 Mn in 2034, 8.2% CAGR.
India Neuropathic Pain Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Neuropathic Pain Treatment Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the neuropathic Pain Treatment market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the neuropathic Pain Treatment market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the neuropathic Pain Treatment market.

Competitive Landscape for Neuropathic Pain Treatment Market in India

The neuropathic Pain Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuropathic Pain Treatment Market in India

Neuropathic Pain Treatment in India: rules and payment

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for neuropathic Pain Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuropathic Pain Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuropathic Pain Treatment in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 12th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 13th highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 13th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuropathic Pain Treatment market in India?
Placeholder estimate: about $187.8 Mn in 2025, rising to about $381.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuropathic Pain Treatment market in India growing?
Placeholder estimate: about 8.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuropathic Pain Treatment market report cover?
The report splits the market by drug class (Anticonvulsants, Antidepressants, Topical Agents, Opioids and more), indication (Diabetic Neuropathy, Postherpetic Neuralgia, Spinal Cord Injury) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Neuropathic Pain Treatment market?
Key players include Pfizer Inc., Eli Lilly and Company, Vertex Pharmaceuticals, Grunenthal and Daiichi Sankyo Company.
What is driving the Neuropathic Pain Treatment market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the neuropathic Pain Treatment market.
Who regulates Neuropathic Pain Treatment in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How much research is published on Neuropathic Pain Treatment?
PubMed lists 110 papers on Neuropathic Pain Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on brain and nerves and pain

See the topic